Egalet Ramps Up Commercial Ahead Of Abuse-Deterrent Pain Drug Filing
This article was originally published in The Pink Sheet Daily
The specialty pharma has relaunched two drugs for pain – Sprix and Oxaydo – supported by a 50-person sales team, laying the groundwork to eventually bring to market an abuse-deterrent, extended-release morphine product.
You may also be interested in...
Acura Pharmaceuticals’ stock fell 11% May 28 after the company revealed that FDA advised an abuse liability study for its hydrocodone/acetaminophen product would not support an abuse liability claim.
Abuse-deterrent opioids address a serious unmet need and help differentiate brands from the field of generics, but so far Purdue’s OxyContin remains the only opioid on the market with abuse-deterrent claims, even though FDA recently approved two new opioid analgesics.
The company will cut 340 positions, primarily affecting Zulresso commercial operations, to save $170m, after announcing it will need to run new trials to support the regulatory plan for zuranolone.